Cryoport Q2 revenue $56.2M (+498% YoY); record trials, positive adjusted EBITDA

Cryoport, Inc.

2022-Q2 EPS reported -$0.29 revenue$109,475,000

Revenue $56.2M, up 498% YoY; organic growth 55%; Biopharma/Pharma up 431%.
Net loss $5.4M vs $5.8M loss a year ago; net loss per share $0.16 vs $0.15.
Adjusted EBITDA $5.9M vs ($2.5M) loss; gross margin 45.2% vs 54.6%.
Supporting 561 clinical trials and 8 commercial therapies; acquired F-airGate and CTSA in Q2.
Cash $349.4M after public offering; expects up to 9 MAA/BLA filings in H2 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.